Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Public ClinicalTrials.gov record NCT00984126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A
Study identification
- NCT ID
- NCT00984126
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 214 participants
Conditions and interventions
Conditions
Interventions
- turoctocog alfa Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Months to 70 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2009
- Primary completion
- Jun 27, 2016
- Completion
- Jun 28, 2016
- Last update posted
- Jul 26, 2017
2009 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Phoenix | Arizona | 85016-7710 | — |
| Novo Nordisk Investigational Site | Long Beach | California | 90806 | — |
| Novo Nordisk Investigational Site | Tampa | Florida | 33607 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30322 | — |
| Novo Nordisk Investigational Site | Iowa City | Iowa | 52242 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02115 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45229 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45404 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97239 | — |
| Novo Nordisk Investigational Site | Providence | Rhode Island | 02903 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37232-9830 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00984126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2017 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00984126 live on ClinicalTrials.gov.